Proteolysis targeting chimeras in non-small cell lung cancer.
暂无分享,去创建一个
[1] Zhaofu Wang,et al. HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations. , 2022, Molecular cancer therapeutics.
[2] Y. Mitsuishi,et al. Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? , 2022, BMC cancer.
[3] F. Kaye,et al. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers , 2022, Journal of Hematology & Oncology.
[4] Yongyi Mao,et al. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. , 2022, Journal of medicinal chemistry.
[5] John Paul Shen,et al. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). , 2022, Journal of Clinical Oncology.
[6] A. Adjei,et al. Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer , 2022, Cancer research and treatment.
[7] Zeyu Cai,et al. Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues. , 2022, Journal of medicinal chemistry.
[8] Jian Li,et al. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation. , 2022, ACS medicinal chemistry letters.
[9] F. Grossi,et al. Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib , 2022, Clinical pharmacology : advances and applications.
[10] Qihua Zhu,et al. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. , 2022, Bioorganic chemistry.
[11] P. Xing,et al. Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis , 2021, Evidence-based complementary and alternative medicine : eCAM.
[12] Wen-jun Tian,et al. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer , 2021, Current opinion in oncology.
[13] Jinhua Luo,et al. FAK-Targeting PROTAC Demonstrates Enhanced Antitumor Activity against KRAS Mutant Non-Small Cell Lung Cancer. , 2021, Experimental cell research.
[14] Dongming Xing,et al. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. , 2021, European journal of medicinal chemistry.
[15] Fang Wu,et al. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.
[16] A. Imagawa,et al. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis , 2021, AntiCancer Research.
[17] M. Tsao,et al. Mechanism of drug tolerant persister cancer cells: The landscape and clinical implication for therapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] D. Manna,et al. LYTACs: An Emerging Tool for the Degradation of Non‐Cytosolic Proteins , 2021, ChemMedChem.
[19] Kristin K. Brown,et al. The PROTACtable genome , 2021, Nature Reviews Drug Discovery.
[20] B. Jiang,et al. Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. , 2021, Journal of medicinal chemistry.
[21] R. Govindan,et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.
[22] J. Soh,et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] Jinyun Dong,et al. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy , 2021, Frontiers in Pharmacology.
[24] Bin Yu,et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy , 2021, Journal of Hematology & Oncology.
[25] P. Park,et al. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific , 2021, Nature Communications.
[26] B. Jiang,et al. Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems. , 2021, European journal of medicinal chemistry.
[27] Lixia Chen,et al. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. , 2021, Journal of medicinal chemistry.
[28] N. London,et al. The rise of covalent proteolysis targeting chimeras. , 2021, Current opinion in chemical biology.
[29] Y. Niu,et al. A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy , 2021, Translational andrology and urology.
[30] O. Margalit,et al. Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades , 2021, Journal of oncology.
[31] Kai Wang,et al. Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti‐tumor immunity in non‐small cell lung cancer , 2020, Drug development research.
[32] Xiangshu Xiao,et al. PROTACs to address the challenges facing small molecule inhibitors. , 2020, European journal of medicinal chemistry.
[33] B. Cornelissen,et al. PARP Inhibitors in Cancer Diagnosis and Therapy , 2020, Clinical Cancer Research.
[34] Shaomeng Wang,et al. A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo , 2020, Neoplasia.
[35] Haolan Lei,et al. Discovery of potent small molecule PROTACs targeting mutant EGFR. , 2020, European journal of medicinal chemistry.
[36] V. Dötsch,et al. Ubiquitination in the ERAD Process , 2020, International journal of molecular sciences.
[37] P. Jänne,et al. Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. , 2020, Angewandte Chemie.
[38] C. Crews,et al. Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs , 2020, ACS central science.
[39] Xiaoju Wang,et al. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. , 2020, Bioorganic & medicinal chemistry letters.
[40] Lin-jiang Tong,et al. Design and synthesis of selective degraders of EGFRL858R/T790M mutant. , 2020, European journal of medicinal chemistry.
[41] B. Jiang,et al. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. , 2020, European journal of medicinal chemistry.
[42] D. Planchard,et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. , 2020, Critical reviews in oncology/hematology.
[43] San-qi Zhang,et al. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). , 2020, European journal of medicinal chemistry.
[44] Xian Chen,et al. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-molecule Degraders. , 2020, Journal of medicinal chemistry.
[45] Ying Cheng,et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.
[46] A. Ferrando,et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity , 2019, Nature Medicine.
[47] Youwei Xu,et al. Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. , 2019, Journal of medicinal chemistry.
[48] C. Bouzin,et al. Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer , 2019, Cancers.
[49] E. Giovannetti,et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.
[50] Rafał Bartoszewski,et al. Primary endothelial cell–specific regulation of hypoxia‐inducible factor (HIF)‐1 and HIF‐2 and their target gene expression profiles during hypoxia , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[51] J. Barrett,et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] Chi-Hoon Park,et al. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). , 2018, Biochemical and biophysical research communications.
[53] J. Barrett,et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] C. Crews,et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance , 2018, Communications Biology.
[55] Y. Xiong,et al. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). , 2018, European journal of medicinal chemistry.
[56] P. Jänne,et al. Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). , 2018, Journal of medicinal chemistry.
[57] Yong-xiao Cao,et al. Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. , 2018, European journal of medicinal chemistry.
[58] Yunpeng Liu,et al. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients , 2018, Clinical Cancer Research.
[59] B. Stockwell,et al. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele. , 2018, Biochemistry.
[60] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[61] Jing Wang,et al. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.
[62] Daniel H. Miller,et al. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1 , 2017, Nature Communications.
[63] F. Hirsch,et al. Comprehensive Analysis of EGFR‐Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[64] P. Stephens,et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. , 2017, Lung cancer.
[65] Dana S. Neel,et al. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma , 2017, npj Precision Oncology.
[66] C. Crews,et al. Targeted Protein Degradation by Small Molecules. , 2017, Annual review of pharmacology and toxicology.
[67] A. Mansfield,et al. S768I Mutation in EGFR in Patients with Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[68] C. Amos,et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. , 2016, Cancer genetics.
[69] Chandra Sekhar Pedamallu,et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.
[70] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[71] Abdel Kareem Azab,et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.
[72] Dong-Wan Kim,et al. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[73] F. Sinicrope,et al. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism* , 2015, The Journal of Biological Chemistry.
[74] R. Govindan,et al. Genomic alterations in lung adenocarcinoma. , 2015, The Lancet. Oncology.
[75] L. Sequist,et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies , 2015, Clinical Cancer Research.
[76] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[77] C. Gambacorti-Passerini,et al. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK , 2015, Cancer medicine.
[78] M. Ladanyi,et al. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[79] C. Crews,et al. Chemical biology: Greasy tags for protein removal , 2012, Nature.
[80] A. Iafrate,et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.
[81] C. Cole,et al. COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.
[82] J. Guan,et al. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. , 2011, Advanced drug delivery reviews.
[83] T. Corson,et al. Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins , 2011, Nature chemical biology.
[84] C. Tse,et al. Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.
[85] S. Ishikawa,et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway , 2007, Cancer science.
[86] W. Denny,et al. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. , 1995, Journal of medicinal chemistry.
[87] Xiaojian Zhang,et al. Development of Hypoxia-activated PROTAC Exerting More Potent Effect in Tumor Hypoxia than in Normoxia , 2021, Chemical Communications.